27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
DNA sequencing and array-based technologies company Illumina, Inc. (NASDAQ:ILMN) pre-announced second-quarter results Thursday that represent a "big miss" versus expectations, according to Bank of America Merrill Lynch.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Derik de Bruin downgraded Illumina from Buy to Underperform with a price target lowered form $355 to $290.
The Thesis
Illumina said Thursday it expects second-quarter revenue to be roughly flat year-over-year at $835 million, which is short of the $890 million expected, de Bruin said in a Friday note. (See his track record here.)
The miss can be attributed to three areas, the analyst said:
- A sizable sequencing systems and consumables purchase that will close later in 2019.
- Softness in the direct-to-consumer genomic market.
- Low to mid-throughput NGS systems and consumables.
On top of a weak second-quarter pre-announcement, Illumina also lowered its full-year sales growth expectations from 13%-14% to 6%.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The revision is "particularly surprising" after management offered positive commentary over recent months, de Bruin said.
Despite a double downgrade to a bearish stance, the analyst said he remains "emphatically bullish" on the long-term potential and opportunity in the sequencing market.
The ongoing drop in the cost of sequencing has resulted in the company expanding the number of applications, and multiple new markets such as liquid biopsy and population genomics remain in the very early stages, he said.
Investors should view BofA's bearish stance as merely a function of near-term uncertainty and not a reflection of long-term fundamentals, de Bruin said.
Price Action
Illumina shares were down 15.91% at $305.80 at the time of publication Friday.
Related Links:
Illumina Shares Slammed On Guidance Warning
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.